E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Posted ContentDOI
Clonal Evolution of Acute Myeloid Leukemia Revealed by High-Throughput Single-Cell Genomics
Kiyomi Morita,Kiyomi Morita,Feng Wang,Katharina Jahn,Jack Kuipers,Yuanqing Yan,Jairo Matthews,Latasha Little,Curtis Gumbs,Shujuan Chen,Jianhua Zhang,Xingzhi Song,Erika Thompson,Keyur P. Patel,Carlos E. Bueso-Ramos,Courtney D. DiNardo,Farhad Ravandi,Elias Jabbour,Michael Andreeff,Jorge E. Cortes,Marina Konopleva,Kapil N. Bhalla,Guillermo Garcia-Manero,Hagop M. Kantarjian,Niko Beerenwinkel,Nicholas Navin,P. Andrew Futreal,Koichi Takahashi +27 more
TL;DR: High-throughput single-cell DNA sequencing for acute myeloid leukemia revealed clonal relationship, architecture, and evolution of AML driver genes with unprecedented resolution, and illuminated the role of clonal diversity in therapeutic resistance, relapse and clinical outcome in AML.
Journal ArticleDOI
Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy.
Hussein A. Abbas,Zoe Alaniz,Sean G Mackay,Matthew Cyr,Jing Zhou,Ghayas C. Issa,Mansour Alfayez,Jairo Matthews,Steven M. Kornblau,Elias Jabbour,Guillermo Garcia-Manero,Marina Konopleva,Michael Andreeff,Naval Daver +13 more
TL;DR: In this article, a multiplexed immune assay was used to assess the functional states of CD4+ and CD8+ cells at a single-cell level in pretherapy bone marrows in 16 patients with relapsed/refractory acute myeloid leukemia (AML) treated with azacitidine/nivolumab.
Journal ArticleDOI
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia
Nicholas J. Short,Hagop M. Kantarjian,Koji Sasaki,Jorge E. Cortes,Farhad Ravandi,Deborah A. Thomas,Guillermo Garcia-Manero,Issa F. Khouri,Partow Kebriaei,Richard E. Champlin,Sherry Pierce,Ghayas C. Issa,Marina Konopleva,Tapan M. Kadia,Carlos E. Bueso-Ramos,Joseph D. Khoury,Nitin Jain,Susan O'Brien,Elias Jabbour +18 more
TL;DR: The role of day 14 (D14) bone marrow assessment in detecting increased blasts in patients undergoing induction for acute lymphoblastic leukemia (ALL) is not well defined.
Journal ArticleDOI
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
Jorge E. Cortes,Alfonso Quintás-Cardama,Elias Jabbour,Susan O'Brien,Srdan Verstovsek,Gautam Borthakur,Farhad Ravandi,Guillermo Garcia-Manero,Elizabeth M. Burton,Jenny Shan,Hagop M. Kantarjian +10 more
TL;DR: CCyR is associated with the greatest survival benefit among patients treated with second-line therapy or beyond and remains the optimal cytogenetic goal of therapy.
Journal ArticleDOI
Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia
Natalia Baran,Alessia Lodi,Yogesh Dhungana,Shelley M. Herbrich,Meghan Collins,Shannon R. Sweeney,Renu Pandey,Anna Skwarska,S. Patel,Mathieu Tremblay,Vinitha Mary Kuruvilla,Antonio Cavazos,Mecit Kaplan,Marc O. Warmoes,Diogo F.T. Veiga,Kenichi Furudate,Shanti Rojas-Sutterin,André Haman,Yves Gareau,Anne Marinier,Helen Ma,Karine Harutyunyan,May Daher,Lucia Garcia,Gheath Alatrash,Sujan Piya,Vivian Ruvolo,Wentao Yang,Sriram S. Shanmugavelandy,Ningping Feng,J. Gay,Di Du,Jun Yang,Fieke W Hoff,Marcin Kamiński,Katarzyna Tomczak,R. Eric Davis,Daniel Herranz,Adolfo A. Ferrando,Elias Jabbour,M. Emilia Di Francesco,David T. Teachey,Terzah M. Horton,Steven M. Kornblau,Katayoun Rezvani,Guy Sauvageau,Mihai Gagea,Michael Andreeff,Koichi Takahashi,Joseph R. Marszalek,Philip L. Lorenzi,Jiyang Yu,Stefano Tiziani,Trang Hoang,Marina Konopleva +54 more
TL;DR: In this article , the authors identify OxPhos as a critical pathway for leukemia cell survival and demonstrate a direct relationship between NotCH1, elevated Oxphos gene expression, and acquired chemoresistance in pre-leukemic and leukemic models.